Partial
Mostly Aligned
Patient Risk:
Low
Summary
The clinical/ingredient and indication-related claims are supported by the provided label excerpts. However, the copay card availability claim is not addressed in the supplied prescribing information, making it unsupported under label-only evaluation.
Category Scores
Accurate Statements
Stiolto Respimat is a prescription medication used for long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD.
Indications and Usage: “STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.”
Stiolto Respimat combines tiotropium and olodaterol.
Clinical Pharmacology: “STIOLTO RESPIMAT contains both tiotropium and olodaterol.”; Dosage Forms/Strengths: “STIOLTO RESPIMAT consists… containing a combination of tiotropium bromide… and olodaterol…”
Tiotropium in Stiolto Respimat is an anticholinergic.
The provided excerpt explicitly lists tiotropium as an anticholinergic: “tiotropium bromide (anticholinergic)” (from the prompt’s provided drug/active ingredient section).
Olodaterol in Stiolto Respimat is a long-acting beta2-adrenergic agonist (LABA).
The provided excerpt explicitly lists olodaterol as a LABA: “olodaterol (long-acting beta-2-adrenergic agonist, LABA)” (from the prompt’s provided drug/active ingredient section).
Unsupported Statements
Information regarding the specific availability of a Stiolto Respimat copay card for 2026 is not yet publicly disclosed.
The supplied FDA-approved prescribing information excerpts do not contain any statements about copay card availability or reimbursement programs, so this claim cannot be supported using only the provided label content.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Only one claim (copay card availability) is unsupported by the provided label excerpts; it does not directly affect labeled clinical safety or dosing decisions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Copay card availability for 2026 is not addressed in the provided prescribing information excerpts and is therefore unsupported under label-only evaluation.
Suggested Improvement
Remove or qualify statements about copay card availability so that only label-supported information is presented.